Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Breast Cancer Trial Results

  • Trastuzumab after Chemotherapy Is Effective in HER2-Positive Breast Cancer
    (Posted: 05/06/2011) - Treatment with trastuzumab for 1 year following standard chemotherapy improved disease-free survival in women with HER2-positive early breast cancer, according to 4-year follow-up results of the Herceptin Adjuvant (HERA) trial reported February 25, 2011, in Lancet Oncology.
  • Sentinel Lymph Node Occult Metastases Have Minimal Survival Effect in Node-Negative Breast Cancer Patients
    (Posted: 04/26/2011) - Detailed examination of sentinel lymph node tissue from breast cancer patients revealed previously unidentified metastases in about 16% of the samples, but the difference in 5-year survival between patients with and without these metastases was very small and likely not clinically meaningful. The results were published in the February 3, 2011 New England Journal of Medicine.
  • Some Women May Not Need More Extensive Lymph Node Surgery for Breast Cancer
    (Posted: 03/31/2011) - Results from a randomized clinical trial published February 9, 2011, in the Journal of the American Medical Association demonstrate that axillary lymph node dissection provided no additional survival benefit when compared with sentinel lymph node biopsy in women with small breast tumors and minimal lymph node metastasis who were treated with lumpectomy, whole-breast radiotherapy, and adjuvant systemic therapy.
  • When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
    (Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
  • Home Care Nursing Improves Cancer Symptom Management
    (Posted: 12/16/2009) - Home care nursing (HCN) improves the management of symptoms in breast and colorectal cancer patients who take the oral chemotherapy drug capecitabine, according to a study published online November 16, 2009, in the Journal of Clinical Oncology.
< Previous  1 2 3 4 5